Pricing Log in Create free account
Saturday 17 October 2026 Export APRE’s income statement to Excel — free account

Aprea Therapeutics, Inc.

APRE Healthcare Biotechnology

Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024. In the quarter to June 2026, revenue fell 98.4%, EPS grew 86.8% and free cash flow fell 5.22%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.58 0.04 −6.45%
Market cap
$7.8M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
1/9
Altman Z
−30.12
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.06
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — 2 2 — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 78.57%

Capital & Financial Ratios $m

Market Cap 7.78
Revenue 0.29
Net Income (12.31)
Free Cash Flow (12.19)
Net Debt (41.23)
Current Ratio 13.55 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.95) (negative: loss-making)
P/S ratio 108.58 (above 10: high)
P/B ratio 0.81
Past 5Y EPS Growth —
This Y EPS Growth 83.55% (at or above 15%: strong)
Next Y EPS Growth (11.02%) (below 0%: weak)
Next Y revenue growth 42.93% (at or above 10%: strong)
Next 5Y EPS Growth 43.58% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −35.7×, against a ten-year median of −7.6×; over the ten years it ranged from −124× in 2026 to 5.4× in 2026.
P/B against its own 10 years 45.80%
10-year low 10-year high
EV/FCF against its own 10 years 78.09%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 22 23 15 41
Receivables — — — —
Inventory — — — —
Other — — — —
23 24 16 42
2023 2024 2025 Q'26
Payables 2 1 1 1
ST’ Debt — — — —
Other — — — —
4 3 3 3

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (30.62%) (21.42%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 0 0 0 0 0
’24 0 1 0 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (4) (3) (3) (3) (13)
’24 (4) (4) (2) (4) (14)
’23 (3) (3) (2) (4) (12)
’22 (5) (9) (7) (4) (25)
’21 (12) (8) (8) (10) (38)
’20 (8) (10) (11) (13) (42)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (4) (3) (3) (3) (13)
’24 (4) (4) (2) (4) (14)
’23 (3) (3) (2) (4) (12)
’22 (5) (9) (7) (4) (25)
’21 (12) (8) (8) (10) (38)
’20 (8) (10) (11) (13) (42)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.22) (0.07) — — —
’25 (0.66) (0.53) (0.47) (0.32) (1.93)
’24 (0.67) (0.58) (0.64) (0.49) (2.35)
’23 (1.34) (0.87) (0.86) (0.92) (3.95)
’22 (7.20) (86.80) (2.40) (0.92) (67.99)
’21 (9.20) (9.60) (9.00) (7.20) (34.80)
’20 (9.00) (15.60) (11.60) (14.60) (50.60)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 302.00 94.60 55.76 6.08 0.47 2.15 0.84

Analyst estimates 2026–2028

Powerpack
High — — — 1,062.20 920.00 169.20 64.20 12.00 8.85 5.00
People
People Employees — — 14 13 17 16 9 7 8 8
Revenue/emp, $m — — 0.00 0.00 0.00 0.00 0.00 0.08 0.19 0.04
Income, $m
Income, $m Revenue — — — — — — — 1 2 0
Gross margin, % — — — — — — — 100.00 100.00 100.00
EBT — (15) (16) (28) (53) (37) (113) (14) (13) (13)
EBT margin, % — 0.00 0.00 0.00 0.00 0.00 0.00 (2,449.73) (862.42) (4,408.54)
Net income — (15) (16) (28) (53) (37) (113) (14) (13) (13)
Depreciation — 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue — 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.27 0.04
Earnings — (263.49) (269.12) (93.40) (50.60) (34.80) (67.99) (3.95) (2.35) (1.93)
Cash flow — (242.67) (264.30) (89.00) (39.55) (35.41) (15.09) (3.37) (2.46) (1.97)
Capex — 0.00 (0.06) (0.10) (0.02) 0.00 0.00 (0.03) 0.00 0.00
Free cash flow — (242.67) (264.37) (89.10) (39.57) (35.41) (15.09) (3.39) (2.46) (1.97)
Book value — 0.00 1,059.87 414.01 73.22 46.52 15.48 4.69 3.50 1.90
Shares, m — 0 0 0 1 1 2 4 6 7
Valuation, ×
Valuation, × P/E — — — — — — — 0.00 0.00 0.00
P/S — — — — — — — 0.00 12.06 19.45
P/B — — — — — — — 1.07 0.94 0.45
EV/Sales — — — — — — — 0.00 (3.14) (31.65)
EV/FCF — — — — — — — 0.29 0.35 0.70
Cash, $m
Cash, $m Operating cash flow — (14) (15) (27) (42) (38) (25) (12) (14) (13)
Capex — — 0 0 0 — — 0 0 —
Free cash flow — (14) (15) (27) (42) (38) (25) (12) (14) (13)
Balance, $m
Balance, $m Working capital — — 61 124 77 49 27 18 20 13
Total debt — — — 1 — — — — — —
Net debt — — (66) (130) (89) (53) (29) (22) (23) (15)
Shareholders’ equity — — 61 124 77 50 26 17 19 12
Returns, %
Returns, % ROA — (46.02) (47.04) (28.11) (47.24) (49.63) (259.05) (54.11) (55.58) (63.14)
ROIC — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE — 0.00 (42.66) (77.08) (53.04) (58.51) (299.83) (67.08) (71.47) (79.37)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025

Charts ten years each

Aprea Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SNTI Senti Biosciences, Inc. $8.1M — (loss-making) — (loss-making) −98.68% (below 0%: shrinking) n/m −7.48% (below 0%: shrinking) 100.00% (85,229.41%) Compare
QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR $8.1M — (loss-making) — — n/m −510.28% (below 0%: shrinking) 0.00% 0.00% Compare
XTLB XTL Biopharmaceuticals Ltd. $8.1M — (loss-making) — −39.32% (below 0%: shrinking) n/m +46.78% (above 0%: growing) 0.00% 0.00% Compare
KPTI Karyopharm Therapeutics Inc. $8.0M — (loss-making) — (loss-making) −11.86% (below 0%: shrinking) n/m −33.34% (below 0%: shrinking) 96.75% (67.38%) Compare
CNSP CNS Pharmaceuticals, Inc. $7.9M — (loss-making) — — n/m +33.70% (above 0%: growing) 0.00% 0.00% Compare
APRE Aprea Therapeutics, Inc. $7.8M — (loss-making) — (loss-making) −98.40% (below 0%: shrinking) n/m −5.22% (below 0%: shrinking) 100.00% 0.00%
SNGX Soligenix Inc. $7.7M — (loss-making) — (loss-making) −98.89% (below 0%: shrinking) n/m +37.83% (above 0%: growing) 0.00% 0.00% Compare
CURX Curanex Pharmaceuticals Inc $7.6M — (loss-making) — — n/m −272.32% (below 0%: shrinking) — 0.00% Compare
MBRX Moleculin Biotech, Inc. $7.6M 0.0× — — n/m −19.26% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $7.9M — — −69.00% — −13.37% 0.00% 0.00%

All 614 Biotechnology stocks →

Aprea Therapeutics, Inc. (APRE) key facts

  • Concern: Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
  • Aprea Therapeutics, Inc. (APRE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, APRE traded at $0.58, a market capitalization of $7.8 million.
  • Return on equity was −79.4% and debt-to-equity 0.00.
  • Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −30.12 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Aprea Therapeutics, Inc. (APRE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/APRE · Data as of Dec 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com